Liav Abraham

In a report published Tuesday, Citigroup analyst Liav Abraham reiterated a Buy rating and $49.00 price target on Zoetis (NYSE: ZTS). In the report, Citigroup noted, “Following today's announcement of a pending ACT/AGN deal, coupled with Pershing Square's announcement of an 8.3% stake in the company...

Citi raised its price target on Actavis plc (NYSE: ACT) from $250 to $310. Analyst Liav Abraham was “confident in management’s ability to successfully integrate” Allergan, Inc. (NYSE: AGN) and believed the “pro-forma entity will benefit from a durable and highly cash...

In a report published Monday, Citigroup analyst Liav Abraham initiated coverage on DBV Technologies (NASDAQ: DBVT) with a Buy rating and $48.00 price target. In the report, Citigroup noted, “The market is not fully appreciating the value of DBV's technology for the treatment of severe allergies, in...

Allergan, Inc.'s (NYSE: AGN) acquisition by Valeant Pharmaceuticals Intl Inc (NYSE: VRX) is looking less likely, in light of a recent move by activist investor Bill Ackman, an analyst said Wednesday. Ackman made a "concession of defeat" in efforts to engineer an Allergan takeover...

In a report published Wednesday, Citigroup analyst Liav Abraham reiterated a Buy rating on Zoetis Inc (NYSE: ZTS), and raised the price target from $44.00 to $49.00. In the report, Citigroup noted, “Following its accumulation of a 9.7% stake in AGN earlier this year, activist hedge fund Pershing...

Shares of Actavis plc (NYSE: ACT) are down nearly 2.5 percent in the past month during which it closed a $25 billion acquisition of Forest Laboratories (NYSE: FRX). But Citi's Liav Abraham reiterated a Buy rating on Actavis Friday with a price target of $250 citing the July 2 closing, even...

Bernstein analyst Aaron Gal reported that Valeant Pharmaceuticals International's (NYSE: VRX) offer for Allergan (NYSE: AGN) should be in the $190.00 per share range. Gal reported that Valeant should offer $190.00 per share cash or an option of part of the deal in cash. The analyst added if...

On Tuesday, Citigroup raised the price target for Teva Pharmaceuticals (NASDAQ: TEVA) from $60 to $70. Copaxone is a “largely sustainable franchise” for the near-to-medium term, due to a favorable ruling from the U.S. Supreme Court regarding generic drug delay, said analyst Liav Abraham. Shares...

Shares of Teva Pharmaceutical Industries (NYSE: TEVA) are trading higher 1.5 percent to $49.86 after Citigroup added the stock to the U.S. focus list and raised the price target to $60 from $56. Analyst Liav Abraham believes the shares offer the “most attractive risk-reward profile amongst...

Tuesday morning rating updates include an upgrade from Citigroup analyst Liav Abraham, boosting Allergen (NYSE: AGN) from Neutral to Buy, with a price rating of $130 from $95. Citigroup is sold on Allergan's long-term growth with strong balance sheet and cash flow to back up their rating change...

In a report published Tuesday, Citigroup analyst Liav Abraham reiterated a Buy rating on Endo Health Solutions (NASDAQ: ENDP), and raised the price target from $43.00 to $70.00. In the report, Citigroup noted, “We view Endo's proposed acquisition of Paladin as a highly strategic, innovative deal...

In a report published Friday, Citigroup analyst Liav Abraham initiated coverage on Actavis PLC (NYSE: ACT) with a Buy rating and $172.00 price target. In the report, Citigroup noted, “Initiating with Buy and Target Price of $172. Our favored name amongst the multinational generic companies – We...

In a report published Friday, Citigroup analyst Liav Abraham initiated coverage on Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) with a Buy rating and $47.00 price target. In the report, Citigroup noted, “We see the potential for value to be unlocked over the next 12 months as investors look...